No images? Click here Friday, 7 August 2026    WHO Technical Advisory Group recommends Ervebo vaccine to be evaluated in vaccine trial for Bundibugyo virus disease in the Democratic Republic of the Congo On 7 August 2026, the WHO Technical Advisory Group on candidate vaccine prioritization (TAG-CVP) for Bundibugyo virus disease (BDBV) outbreak response released a new report regarding possible candidate vaccines for Bundibugyo virus disease. The members recommended Ervebo, the only vaccine licensed Ebola vaccine, be prioritized for inclusion in a randomized clinical trial in the context of the ongoing outbreak. WHO advisory groups were convened following the declaration on 16 May of a Public Health Emergency of International Concern for the Ebola outbreak caused by the Bundibugyo virus (BVD) in the Democratic Republic of the Congo. The groups met subsequently to review the candidate vaccine and treatment landscape for this type of Ebola disease and issued a first set of recommendations. At that time, the TAG-CVP recommended that Ervebo, the only licensed Ebola vaccine (against Ebola virus disease also known as Ebola Zaire), should not be used outside carefully designed research settings, to allow for its performance against BVD to be assessed.  On 31 July, the members of the advisory group met for the third time to review new data that had become available on Ervebo. The TAG-CVP members reviewed preliminary data from animal studies showing that Ervebo offered some level of cross-protection against BVD in animals, particularly against death from the disease. The group assessed the levels of safety, efficacy, availability and implementation for this potential vaccine and members agreed that there were no safety concerns for this potential vaccine if used in the context of a BDBV outbreak in which contacts of cases are vaccinated. Therefore, the members recommended Ervebo to be prioritized for inclusion in a randomized clinical trial in the context of the ongoing outbreak and in the absence of specific BDBV vaccines. The experts noted that efficacy of Erbevo against BVD disease and transmission would still need to be proven, and that a specific Bundibugyo vaccine would remain the preferred option, although preliminary data for candidate vaccines are yet to be available. Production and access to the vaccines, if sufficient efficacy data would arise, would also need to be facilitated at scale and made available to the affected populations. Read the full report here.  Related links WHO Technical Advisory Group on Candidate Vaccine Prioritization (TAG-CVP)   Media contacts:  mediainquiries@who.int You are receiving this NO-REPLY email because you are included on a WHO mail list. If you have been forwarded this update you can click here to subscribe. Journalists may send feedback to WHO Media Team           Share    Tweet    Share    Forward  World Health Organization, Avenue Appia 20, 1202 Geneva 27, Switzerland  Unsubscribe